Second line study analysis published

Dear RDI subscriber / HIV-TRePS user,

Our latest study, now published online in HIV Medicine, shows that HIV-TRePS performs comparably well with, or without, a genotype and significantly outperforms genotyping as a predictor of response to treatment.

The study compared the performance of the two sets of models used to power HIV-TRePS that do, and do not, require a genotype for their predictions of response. The models predicted virological response for 99 three-drug regimens for patients on a failing regimen of two nucleoside/nucleotide reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor in the Second-Line study.

aEURc The rankings of alternative regimens by the two sets of models were significantly correlated in the majority of cases.
aEURc The two sets of models identified alternative regimens that were predicted to be effective in 97%-100% of cases.
aEURc The models performed with 72% and 74% accuracy compared with 55% for genotyping with rules-based interpretation (using the Stanford database).

The paper can be viewed here:

We hope you find this of interest.

The RDI team.

Date published: 17th April 2014


Join the RDI mailing list

Enter your email address below to start receiving the RDI newsletter.

You can unsubscribe at any time. View the RDI privacy policy.